Recent Advancements in the Design of Nanodelivery Systems of siRNA for Cancer Therapy

• Published in: Molecular pharmaceutics Vol. 19; no. 12; pp. 4506 - 4526
• Main Authors: Yadav, Dokkari Nagalaxmi, Ali, Mohammad Sadik, Thanekar, Ajinkya Madhukar, Pogu, Sunil Venkanna, Rengan, Aravind Kumar
• Format: Journal Article
• Language: English
• Published: American Chemical Society 05.12.2022
• Subjects: siRNA delivery; RNAi; cancer; therapy; nanocarriers
• ISSN: 1543-8384; 1543-8392; 1543-8392
• DOI: 10.1021/acs.molpharmaceut.2c00811

RNA interference (RNAi) has increased the possibility of restoring RNA drug targets for cancer treatment. Small interfering RNA (siRNA) is a promising therapeutic RNAi tool that targets the defective gene by inhibiting its mRNA expression and stopping its translation. However, siRNAs have flaws like poor intracellular trafficking, RNase degradation, rapid kidney filtration, off-targeting, and toxicity, which limit their therapeutic efficiency. Nanocarriers (NCs) have been designed to overcome such flaws and increase antitumor activity. Combining siRNA and anticancer drugs can give synergistic effects in cancer cells, making them a significant gene-modification tool in cancer therapy. Our discussion of NCs-mediated siRNA delivery in this review includes their mechanism, limitations, and advantages in comparison with naked siRNA delivery. We will also discuss organic NCs (polymers and lipids) and inorganic NCs (quantum dots, carbon nanotubes, and gold) that have been reported for extensive delivery of therapeutic siRNA to tumor sites. Finally, we will conclude by discussing the studies based on organic and inorganic NCs-mediated siRNA drug delivery systems conducted in the years 2020 and 2021.